Exclusive Summary

• Over 537 million diabetic patients globally provide a massive baseline market, with high potential for off-label growth in NASH/MASH treatments recommended by authoritative guidelines.
• Originator patents have long expired, ensuring no IP barriers and a highly predictable regulatory pathway for fast-track product launch.
• Backed by China's integrated API-to-FDF supply chain, the product offers significant cost advantages, ensuring substantial profit margins for overseas distributors.
• Supported by ICH-compliant CTD dossiers and bioequivalence to the originator, enabling rapid market penetration in emerging regions like LATAM, MENA, and SEA with surging demand for antidiabetic drugs.